Related Experiment Video

Updated: May 6, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

5.7K

Targeting the protein-protein interaction between IRS1 and mutant p110α for cancer therapy

Yujun Hao1, Shuliang Zhao, Zhenghe Wang

  • 11Department of Genetics and Genome Sciences, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA.

Toxicologic Pathology
|November 2, 2013
PubMed

Insights

Targeting the p110α oncogene in cancer is promising. Disrupting the interaction between mutant p110α helical domain proteins and IRS1 inhibits tumor growth, offering a new precision therapy target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Phosphoinositide-3-kinase, catalytic, alpha polypeptide (PIK3CA) is the most frequently mutated oncogene in human cancers.
  • Mutant PIK3CA drives cancer development, making it a key therapeutic target.
  • Developing PIK3CA isoform-specific inhibitors is challenging due to mutation heterogeneity.

Purpose of the Study:

  • To investigate the interaction between PIK3CA mutants and insulin receptor substrate 1 (IRS1).
  • To explore the therapeutic potential of targeting the PIK3CA-IRS1 interaction in cancer.
  • To identify novel strategies for precision cancer therapy against PIK3CA-driven tumors.

Main Methods:

  • Analysis of protein-protein interactions between PIK3CA mutants and IRS1.
  • Assessment of tumor growth inhibition by disrupting the PIK3CA-IRS1 interaction.
  • Characterization of PIK3CA mutations in helical and kinase domains.

Main Results:

  • PIK3CA helical domain mutants, unlike kinase domain mutants, directly associate with IRS1.
  • Disruption of the PIK3CA helical domain mutant-IRS1 interaction significantly inhibits tumor growth.
  • This interaction represents a specific vulnerability in certain PIK3CA-mutant cancers.

Conclusions:

  • The direct interaction between IRS1 and PIK3CA helical domain mutants is a critical oncogenic event.
  • Targeting this specific protein-protein interaction offers a promising avenue for novel precision cancer therapies.
  • This finding opens new possibilities for developing isoform-specific PIK3CA inhibitors.
Keywords:
cancergenomics.molecular biology

More Related Videos

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

10.4K
Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

400

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.5K
Regulation of the Unfolded Protein Response01:31

Regulation of the Unfolded Protein Response

Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.2K